Logo image of OPGN

OPGEN INC (OPGN) Stock Fundamental Analysis

NASDAQ:OPGN - Nasdaq - US68373L5057 - Common Stock - Currency: USD

1.96  -0.34 (-14.78%)

After market: 1.85 -0.11 (-5.61%)

Fundamental Rating

0

OPGN gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. OPGN may be in some trouble as it scores bad on both profitability and health. OPGN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OPGN has reported negative net income.
OPGN had a negative operating cash flow in the past year.
OPGN had negative earnings in each of the past 5 years.
OPGN had a negative operating cash flow in each of the past 5 years.
OPGN Yearly Net Income VS EBIT VS OCF VS FCFOPGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

OPGN's Return On Assets of -897.50% is on the low side compared to the rest of the industry. OPGN is outperformed by 99.12% of its industry peers.
Industry RankSector Rank
ROA -897.5%
ROE N/A
ROIC N/A
ROA(3y)-646.2%
ROA(5y)-422.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OPGN Yearly ROA, ROE, ROICOPGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OPGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OPGN Yearly Profit, Operating, Gross MarginsOPGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

More info and screens

0

2. Health

2.1 Basic Checks

OPGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
OPGN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for OPGN has been increased compared to 5 years ago.
The debt/assets ratio for OPGN is higher compared to a year ago.
OPGN Yearly Shares OutstandingOPGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
OPGN Yearly Total Debt VS Total AssetsOPGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -160.99, we must say that OPGN is in the distress zone and has some risk of bankruptcy.
OPGN's Altman-Z score of -160.99 is on the low side compared to the rest of the industry. OPGN is outperformed by 98.42% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -160.99
ROIC/WACCN/A
WACC10.94%
OPGN Yearly LT Debt VS Equity VS FCFOPGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

OPGN has a Current Ratio of 0.05. This is a bad value and indicates that OPGN is not financially healthy enough and could expect problems in meeting its short term obligations.
OPGN has a worse Current ratio (0.05) than 99.65% of its industry peers.
A Quick Ratio of 0.05 indicates that OPGN may have some problems paying its short term obligations.
OPGN has a Quick ratio of 0.05. This is amonst the worse of the industry: OPGN underperforms 99.65% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
OPGN Yearly Current Assets VS Current LiabilitesOPGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

OPGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.19%, which is quite impressive.
Looking at the last year, OPGN shows a very negative growth in Revenue. The Revenue has decreased by -12.39% in the last year.
The Revenue has been growing slightly by 3.02% on average over the past years.
EPS 1Y (TTM)79.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.64%
Revenue 1Y (TTM)-12.39%
Revenue growth 3Y-6.74%
Revenue growth 5Y3.02%
Sales Q2Q%-81.52%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.72%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-0.26%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OPGN Yearly Revenue VS EstimatesOPGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
OPGN Yearly EPS VS EstimatesOPGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OPGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OPGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OPGN Price Earnings VS Forward Price EarningsOPGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OPGN Per share dataOPGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OPGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OPGEN INC

NASDAQ:OPGN (8/19/2024, 8:13:00 PM)

After market: 1.85 -0.11 (-5.61%)

1.96

-0.34 (-14.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2024-08-08/amc
Earnings (Next)11-12 2024-11-12/amc
Inst Owners1.19%
Inst Owner Change-100%
Ins Owners1035.79%
Ins Owner Change0%
Market Cap2.65M
Analysts43.33
Price Target3.06 (56.12%)
Short Float %0.16%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-4.33%
Min Revenue beat(2)-72.52%
Max Revenue beat(2)63.87%
Revenue beat(4)1
Avg Revenue beat(4)-13.08%
Min Revenue beat(4)-72.52%
Max Revenue beat(4)63.87%
Revenue beat(8)3
Avg Revenue beat(8)-8.61%
Revenue beat(12)3
Avg Revenue beat(12)-13.34%
Revenue beat(16)5
Avg Revenue beat(16)-12.26%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.99
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-28.18
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-8.08
FCFYN/A
OCF(TTM)-7.73
OCFYN/A
SpS1.98
BVpS-7.93
TBVpS-7.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -897.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-646.2%
ROA(5y)-422.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.53%
Cap/Sales 17.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -160.99
F-Score4
WACC10.94%
ROIC/WACCN/A
Cap/Depr(3y)56.59%
Cap/Depr(5y)35.76%
Cap/Sales(3y)30.71%
Cap/Sales(5y)19.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.64%
EPS Next Y99.72%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.39%
Revenue growth 3Y-6.74%
Revenue growth 5Y3.02%
Sales Q2Q%-81.52%
Revenue Next Year-0.26%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.56%
OCF growth 3YN/A
OCF growth 5YN/A